Limits...
In vivo early intervention and the therapeutic effects of 20(s)-ginsenoside rg3 on hypertrophic scar formation.

Cheng L, Sun X, Hu C, Jin R, Sun B, Shi Y, Cui W, Zhang Y - PLoS ONE (2014)

Bottom Line: Animal studies were done to investigate the combining therapeutic effects of 20(S)-ginsenoside Rg3 (Rg3) on the inflammatory phase of wound healing and HS formation.Topical injection of 4 mg/mL Rg3 can reduce HS formation by 34%.Histological and molecular studies revealed that Rg3 injection inhibits fibroblasts proliferation thus reduced the accumulation of collagen fibers, and down-regulates VEGF expression in the HS tissue.

View Article: PubMed Central - PubMed

Affiliation: Department of Plastic and Reconstructive Surgery, Ninth People's Hospital affiliated to Medical School of Shanghai Jiao Tong University, 639 Zhi Zao Ju Road, Shanghai 200011, People's Republic of China.

ABSTRACT

Background: Intra-lesional injections of corticosteroids, interferon, and chemotherapeutic drugs are currently the most popular treatments of hypertrophic scar formation. However, these drugs can only be used after HS is formed, and not during the inflammatory phase of wound healing, which regulates the HS forming process.

Objective: To investigate a new, effective, combining therapeutic and safe drug for early intervention and treatment for hypertrophic scars.

Methods: Cell viability assay and flow cytometric analysis were studied in vitro. Animal studies were done to investigate the combining therapeutic effects of 20(S)-ginsenoside Rg3 (Rg3) on the inflammatory phase of wound healing and HS formation.

Results: In vitro studies showed that Rg3 can inhibit HS fibroblasts proliferation and induce HSF apoptosis in a concentration-dependent manner. In vivo studies demonstrated that Rg3 can limit the exaggerated inflammation, and do not delay the wound healing process, which indicates that Rg3 could be used as an early intervention to reduce HS formation. Topical injection of 4 mg/mL Rg3 can reduce HS formation by 34%. Histological and molecular studies revealed that Rg3 injection inhibits fibroblasts proliferation thus reduced the accumulation of collagen fibers, and down-regulates VEGF expression in the HS tissue.

Conclusion: Rg3 can be employed as an early intervention and a combining therapeutic drug to reduce inflammation and HS formation as well.

Show MeSH

Related in: MedlinePlus

Effect of different concentrations of Rg3 on HSF apoptosis 48 h after treatment.Percentage of apoptotic cells was measured by flow cytometry after annexin-V/propidium iodide (PI) staining. Quandrant 1 indicates live cells; quadrant2 indicates cells in early apoptosis; quadrant 3 indicates cells in late apoptosis; quadrant 4 indicates cells in necrosis.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4264739&req=5

pone-0113640-g003: Effect of different concentrations of Rg3 on HSF apoptosis 48 h after treatment.Percentage of apoptotic cells was measured by flow cytometry after annexin-V/propidium iodide (PI) staining. Quandrant 1 indicates live cells; quadrant2 indicates cells in early apoptosis; quadrant 3 indicates cells in late apoptosis; quadrant 4 indicates cells in necrosis.

Mentions: The number of apoptotic cells increased, as the concentration of Rg3 increased. The corresponding quantities of total cell apoptosis were 5.3±0.61, 9.2±0.5, 15.9±0.4, 36.6±0.4 and 40±0.6% at 25, 50, 75, 100, 200 µg/mL Rg3 (Fig. 3), respectively. Most of the apoptosis of HSFs in each group proved to be early apoptosis, and only a very small percentage stained positive for PI, indicating that the cells were not necrotic (data not shown). The above results indicated that high doses of Rg3 induced HSFs apoptosis in a concentration-dependent way, and that Rg3 is a safe drug with low cell-toxicity which won't cause cell necrosis.


In vivo early intervention and the therapeutic effects of 20(s)-ginsenoside rg3 on hypertrophic scar formation.

Cheng L, Sun X, Hu C, Jin R, Sun B, Shi Y, Cui W, Zhang Y - PLoS ONE (2014)

Effect of different concentrations of Rg3 on HSF apoptosis 48 h after treatment.Percentage of apoptotic cells was measured by flow cytometry after annexin-V/propidium iodide (PI) staining. Quandrant 1 indicates live cells; quadrant2 indicates cells in early apoptosis; quadrant 3 indicates cells in late apoptosis; quadrant 4 indicates cells in necrosis.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4264739&req=5

pone-0113640-g003: Effect of different concentrations of Rg3 on HSF apoptosis 48 h after treatment.Percentage of apoptotic cells was measured by flow cytometry after annexin-V/propidium iodide (PI) staining. Quandrant 1 indicates live cells; quadrant2 indicates cells in early apoptosis; quadrant 3 indicates cells in late apoptosis; quadrant 4 indicates cells in necrosis.
Mentions: The number of apoptotic cells increased, as the concentration of Rg3 increased. The corresponding quantities of total cell apoptosis were 5.3±0.61, 9.2±0.5, 15.9±0.4, 36.6±0.4 and 40±0.6% at 25, 50, 75, 100, 200 µg/mL Rg3 (Fig. 3), respectively. Most of the apoptosis of HSFs in each group proved to be early apoptosis, and only a very small percentage stained positive for PI, indicating that the cells were not necrotic (data not shown). The above results indicated that high doses of Rg3 induced HSFs apoptosis in a concentration-dependent way, and that Rg3 is a safe drug with low cell-toxicity which won't cause cell necrosis.

Bottom Line: Animal studies were done to investigate the combining therapeutic effects of 20(S)-ginsenoside Rg3 (Rg3) on the inflammatory phase of wound healing and HS formation.Topical injection of 4 mg/mL Rg3 can reduce HS formation by 34%.Histological and molecular studies revealed that Rg3 injection inhibits fibroblasts proliferation thus reduced the accumulation of collagen fibers, and down-regulates VEGF expression in the HS tissue.

View Article: PubMed Central - PubMed

Affiliation: Department of Plastic and Reconstructive Surgery, Ninth People's Hospital affiliated to Medical School of Shanghai Jiao Tong University, 639 Zhi Zao Ju Road, Shanghai 200011, People's Republic of China.

ABSTRACT

Background: Intra-lesional injections of corticosteroids, interferon, and chemotherapeutic drugs are currently the most popular treatments of hypertrophic scar formation. However, these drugs can only be used after HS is formed, and not during the inflammatory phase of wound healing, which regulates the HS forming process.

Objective: To investigate a new, effective, combining therapeutic and safe drug for early intervention and treatment for hypertrophic scars.

Methods: Cell viability assay and flow cytometric analysis were studied in vitro. Animal studies were done to investigate the combining therapeutic effects of 20(S)-ginsenoside Rg3 (Rg3) on the inflammatory phase of wound healing and HS formation.

Results: In vitro studies showed that Rg3 can inhibit HS fibroblasts proliferation and induce HSF apoptosis in a concentration-dependent manner. In vivo studies demonstrated that Rg3 can limit the exaggerated inflammation, and do not delay the wound healing process, which indicates that Rg3 could be used as an early intervention to reduce HS formation. Topical injection of 4 mg/mL Rg3 can reduce HS formation by 34%. Histological and molecular studies revealed that Rg3 injection inhibits fibroblasts proliferation thus reduced the accumulation of collagen fibers, and down-regulates VEGF expression in the HS tissue.

Conclusion: Rg3 can be employed as an early intervention and a combining therapeutic drug to reduce inflammation and HS formation as well.

Show MeSH
Related in: MedlinePlus